Publications by authors named "K Swales"
BACKGROUNDPhase 1 study of ATRinhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors.METHODSThe primary objective was safety. Secondary objectives included assessment of antitumor responses and pharmacokinetic (PK) and pharmacodynamic (PD) studies.
View Article and Find Full Text PDFInflammation is a hallmark of cancer. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across malignancies and therapeutic modalities. Whether myeloid inflammation drives progression of prostate cancer in humans remain unclear.
View Article and Find Full Text PDFArticle Synopsis
- - The study explored the effectiveness and safety of using a combination of CDK4/6 inhibitor (palbociclib) and PI3K inhibitor (taselisib), along with the hormone therapy (fulvestrant), in treating advanced ER-positive HER2-negative breast cancer with specific genetic mutations.
- - Results showed that the triplet therapy led to a 37.5% response rate in the targeted patient group, while both doublet and triplet therapies were well tolerated and provided durable disease control.
- - High levels of cyclin E1 and changes in circulating tumor DNA (ctDNA) were linked to shorter progression-free survival, indicating that monitoring these factors could help refine treatment strategies for breast cancer patients.
Purpose: AT13148 is an oral AGC kinase inhibitor, which potently inhibits ROCK and AKT kinases. In preclinical models, AT13148 has been shown to have antimetastatic and antiproliferative activity.
Patients And Methods: The trial followed a rolling six design during dose escalation.
Article Synopsis
- Preclinical studies suggest that combining PARP inhibitors (like olaparib) with PI3K/AKT pathway inhibitors (like capivasertib) is effective for treating certain tumors.
- An investigator-led phase I trial tested this combination on 64 patients with advanced solid tumors, using an intrapatient dose-escalation approach to determine safety and efficacy.
- Results showed that 44.6% of patients experienced clinical benefits, and the combination was well tolerated, indicating potential for further development in future clinical trials.